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Clinical PerspectiveMFM guidance for COVID-19
Rupsa C. Boelig, MD, MS; Gabriele Saccone, MD; Federica Bellussi, MD; Vincenzo Berghella, MDhe World Health Organization hasBOX 1
General guidance for outpatient obstetric practice management in
setting of COVID-19
General obstetric/MFM COVID-19 recommendations
 Prevention of spread should be the number 1 priority.
 Social distancing of at least 6 feet; if not feasible, extended dividers or other
precautions.
 Any elective or non-urgent visits should be postponed.
 Each patient should be called to decide on need for next in-person visit and/or test.
 Any visit that can be done by telehealth should be done that way.
 No support person to accompany patient to outpatient visits unless they are an integral
part of patient care.
Testing-specific recommendations:
 Pregnancy alone in the setting of new flu-like symptoms with negative influenza is
sufficient to warrant COVID-19 testing; test especially if additional risk factors (eg, older,
immunocompromised, advanced HIV, homeless, hemodialysis, etc).
 Symptomatic patients are best triaged via telehealth to assess their need for inpatient
support or supplemental testing; in general, they should be presumed infected and self-
isolate for 14 days. In-person evaluation is not indicated if symptoms are mild.
 Utilize drive-through testing or stand-alone testing rather than in-office testing where
exposure can spread.
 Symptomatic patients who nonetheless arrive to hospital or office should be managed
as if they are COVID-19 positive; so immediately properly isolated in designated areas,
with appropriate (eg, N-95) mask on.T declared coronavirus 2019
(COVID-19) a global pandemic.
Healthcare providers should prepare
internal guidelines covering all aspect of
the organization in order to have their
unit ready as soon as possible. This
document addresses the current
COVID-19 pandemic for maternal-fetal
medicine practitioners.
The goals of the guidelines put forth
here are 2-fold: first, to reduce patient risk
through health care exposure, under-
standing that asymptomatic health sys-
tems/health care providers may become
the most common vector for trans-
mission, and second, to reduce the public
health burden of COVID-19 transmission
throughout the general population.
Box 1 outlines general guidance to
prevent the spread of COVID-19 and
protect our obstetric patients. Section 1
outlines suggested modifications of
outpatient obstetrical (prenatal) visits.
Section 2 details suggested scheduling of
obstetrical ultrasound. Section 3 reviews
suggested modification of nonstress tests
(NSTs) and biophysical profiles (BPPs).
Section 4 reviews suggested visitor policy
for obstetric outpatient office. Section 5
discusses the role of trainees andmedical
education in the setting of a pandemic.
These are suggestions, which can be
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Section 1: Outpatient obstetrical
(prenatal) visits
All new obstetrical intakes should be
completed by telehealth/remotely un-
less the patient describes an urgent Designated separate areas should be crea
patients: increase sanitization; hand sanitizer a
area; wipe down patient rooms after each patien
Practice-specific considerations and recomme
 Meetings should all be virtual/audio/video.
 Keep some providers at home, as feasibl
highest risk (eg, >60 years old and/or como
 Practitioners should be leaders in their uni
for each area (eg, L&D, outpatient; ultrasoun
ISUOG; ACOG; WHO; CDC; etc) and adapt to
cover every scenario. Use this guidance and
much as feasible.
ACOG, American College of Obstetrics and Gynecology; CDC, C
navirus 2019; ISUOG, International Society of Ultrasound in Obstet
fetal medicine; SMFM, Society for Maternal-Fetal Medicine; WHO
Boelig. MFM guidance for COVID-19. Am J Obstet Gynecoproblem, in which case she will be
appointed as an urgent in-person visit.
The standard timing for in-person en-
counters in routine, uncomplicated
pregnancies are described in Table 1.
The hope is that necessary laboratory
work and/or ultrasounds can be done at
the same visit.ted in each unit for suspected COVID-19
vailable at front desk, throughout waiting
t; wipe downwaiting area chairs frequently.
ndations:
e, with clinical duties, especially those at
rbidities).
t. COVID-19 leaders should be designated
d). Use this and other guidance (SMFM;
your specific situation. No guideline can
clinical judgment to avoid any contact as
enters for Disease Control and Prevention; COVID-19, coro-
rics and Gynecology; L&D,labor and delivery;MFM, maternal-
, World Health Organization.
l MFM 2020.
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TABLE 1
Summary of suggested antenatal visit timing in setting of COVID-19
pandemic
Gestational age In-person OB visit Ultrasound Comments
<11 weeksa Telephone OB intake
11e13 weeksb X X (dating/NT) Initial OB lab tests
20 weeks X X (anatomy)
28 weeks X Labs/vaccines
32 weeks X (if indicated) Telehealth
36 weeks X X (if indicated) GBS/HIV screen
37 weeks to delivery Weekly telehealth
and kick counts
Postpartum Telehealth
Use of telehealth visits facilitate blood pressure cuff/kick counts at home so that in-person visits are not necessary. Additional
visits including diabetes control, hypertension, mood disorder, etc may be done remotely with teleheath as well.
COVID-19, coronavirus 2019; GBS, group B strep; NT, nuchal translucency; OB, obstetric.
a Earlier scan may be indicated if at risk for ectopic; b If viability is previously established, consider skipping 11e13 week scan
and offering cell-free DNA.
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Clinical PerspectiveConsideration may also be given
to having laboratory work performed
at lower-volume satellite office sites
in which the ability to accomplishBOX 2
General principles for routine ultraso
diagnosis and minimize exposure ris
Dating ultrasound:
 Combine dating/NT to one ultrasound bas
 If ultrasound earlier in the first trimester (eg
of threatened abortion, pregnancy of unknown
NT ultrasound and offering cell-free DNA scr
screening.
 For patients with unknown LMP or EGA >
Anatomy ultrasound (20e22 weeks)a
 Consider follow-up views in 4e8 weeks r
 Consider serial cervical length for those at
otherwise do once with anatomy ultrasound.
 BMI >40 kg/m2: schedule at 22 weeks to
follow-up.
Growth ultrasounds
 All single third-trimester growth at 32 wee
 Follow-up previa/low-lying placenta at 34e
 Begin serial growth at 28 weeks (not 24 w
 Consider q 6e8 weeks week rather than
NT, nuchal translucency; LMP, last menstrual period; EGA, estim
aOr earlier if desired based on state-specific termination laws.
bConsider forgoing follow-up ultrasound for 1 or 2 suboptimal vi
posterior fossa normal).
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2 AJOG MFM MAY 2020social distancing is more easily
attained, as feasible. Interim tele-
health visits can be scheduled at pro-
vider discretion (eg, at 16, 24, 34unds to maximize perinatal
k
ed on LMP.
, less than 10 weeks) is indicated because
anatomic location, may consider forgoing
eening for those desiring early aneuploidy
14 weeks may schedule as next available.
ather than 1e2 weeks.b
highest risk for spontaneous preterm birth,
reduce risk of suboptimal views/need for
ks.
36 weeks.
eeks) with rare exceptions.
q 4 week follow-up for most patients,
ated gestational age; BMI, body mass index; q, every.
ews (eg, l/s spine not seen well because of fetal position but
l MFM 2020.weeks). Reschedule all obstetric visits
using this paradigm.
Tominimize other in-patient visits, all
patients should be instructed to obtain
blood pressure cuffs if feasible. Some
more health plans may cover the cost of
blood pressure cuffs in the setting of the
coronavirus pandemic. Consider all
other visits by telehealth if feasible.
Postpartum evaluation of cesarean
wound healing or mastitis concerns may
be optimized through the use of photo
upload options available in many elec-
tronic medical record patient portal
programs.Section 2: Scheduling of obstetric
ultrasound
Box 2 summarizes our suggested modi-
fications to ultrasound timing. Table 2
outlines recommendations for specific
antenatal indications. We recognize that
these recommendations are specific to
our practice environment. Maternal-
fetal medicine physicians nationally and
internationally should feel empowered
to adjust as needed based on limitations
in capacity and/or higher incidence of
COVID, which may require further re-
strictions for both patient safety and
public health.
In addition to modifying ultrasound
timing, the routine practice of face-to-
face counseling for ultrasounds should
be adjusted. In most cases ultrasound
findings can be reviewed either over the
phone/telehealth, or in the setting of a
normal routine ultrasound, by the ob-
stetric provider at the next visit. Indeed,
because of resource limitations, many
sites do only have remote communica-
tions for ultrasound finding, and this
technology should be adapted widely to
limit unnecessary patient contact, which
protects both the patient from getting an
infection and the provider from being a
vector.Section 3: Scheduling of nonstress
tests/biophysical profiles
Table 3 illustrates how antenatal sur-
veillance with NSTs/BPPs may be
modified in the setting of the COVID-19
pandemic and the actual increased risk
patients may face in coming into the
TABLE 2
Outline of common indications for growth ultrasound and suggested frequency/timing in setting of COVID-19
pandemic
Indication
Frequency
CommentsOnce q 4 wks q 6e8 wks
Pregestational diabetes mellitus X
Chronic HTN on medications X Once if no meds
Current preeclampsia/gestational HTN X
History of severe preeclampsia X
History of IUGR or SGA X
Current IUGR X
Sickle cell disease X
CKD X
Multiples, mono/dia X
Multiples, mono/mono X
Multiples, di/di X
GDMA2 X
Lupus, no renal dysfunction X
Prior unexplained IUFD X
Organ transplant X
Maternal cardiac disease X
Uncontrolled thyroid disease X
Current tobacco or substance use X
AMA (35 y old) X
Gestational diabetes, A1 X
Chronic HTN, off medications X
Abnormal placentation X At 34e36 wks
Uterine fibroids >5 cm X
Serial growth ultrasound beginning at 28 weeks; 1 time growth at 32 weeks unless otherwise indicated. Practice locations should adjust as needed based on site capacity and risk of COVID exposure.
AMA, advanced maternal age; CKD, chronic kidney disease; COVID-19, coronavirus 2019; Di/Di, dichorionic diamniotic; GDMA2, gestational diabetes-A2; HTN, hypertension; ; IUFD, intrauterine fetal
demise IUGR,intrauterine growth restriction; Mono-Di, monochorionic diamniotic; Mono/Mono, monochorionic diamniotic; q, every; SGA, small for gestational age.
a Consider every 2 week twin-twin transfusion screening.
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Clinical Perspectiveoffice for 30 or more minutes of testing.
In general, we suggest the following
principles:
 Twice-weekly NSTs only for intra-
uterine growth restriction with
abnormal umbilical artery Doppler.
 Limit NSTs initiated <32 weeks. If concurrent ultrasound, perform a
BPP rather than an additional NST
visit.
 In lower-risk patients, such as
advanced maternal age 35e39 years
or body mass index >40 kg/m2 with
no other comorbidities, consider kick
counts instead of NSTs.For patients with gestational hyper-
tension/preeclampsia, plan a weekly visit
in the office with daily blood pressure
checks at home. Weekly visit will include
antenatal testing, blood pressure check,
and labwork drawn in the office to mini-
mize the need for additional visits. These
changes should be relayed to patientswithMAY 2020 AJOG MFM 3
TABLE 3
Summary of common indications for nonstress tests and how we have modified frequency of testing in setting of
additional risks related to COVID-19 exposure and transmission
Indication
for NST
Gestational
age to begin
1 time/wk
Gestational
age to begin
2 times/wk Comments COVID-19a
AMA 36 Fetal kick counts instead of NST
Cholestasis Diagnosis
Decreased fetal movement Diagnosis One time only
Pregestational diabetes 32 36 Weekly only
GDMA2 32 36 Weekly only
Chronic HTN 32 36 weeks if no medications
Gestational HTN Diagnosis Weekly with home BP monitoring
Preeclampsia Diagnosis Weekly with home BP monitoring
CKD 32
IUGR Diagnosis Weekly with Doppler. Substitute
BPP when possible
Elevated Dopplers Diagnosis
SLE 32
Fetal arrhythmia Diagnosis
Mono/Di twins 32
Di/Di twins Only if additional indication
Obesity/BMI >40 kg/m2 32 Fetal kick counts instead of NST
Oligohydramnios Diagnosis
Polyhydramnios Diagnosis Diagnosis or at 32 wks if <32 wk diagnosis.
Only for AFI >30
Prior IUFD 32 1 wk prior to IUFD
Sickle cell disease 32 Kick counts if well controlled
Single umbilical artery 32 Fetal kick counts if normal growth,
normal anatomy, normal genetic screening
AMA, advanced maternal age; BMI, body mass index; BP, blood pressure; BPP, biophysical profile; CKD, chronic kidney diseases; COVID-19, coronavirus 2019; Di/Di, dichorionic diamniotic; GDMA2,
gestational diabetes-A2; HTN, hypertension; ; IUFD, intrauterine fetal demise IUGR, intrauterine growth restriction; Mono-Di, monochorionic diamniotic; NST, nonstress test; SLE, systemic lupus
erythematosus.
a Text in column indicates changes to recommendations in setting of COVID, and no change in practice is suggested if this column is empty.
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BOX 3
Suggested visitor policy for outpatient offices
General outpatient office visitor policy
 There should be no additional family/friend/partner in any outpatient appointment.
 Patients are asked not to bring children.
 Visitor with symptoms at front desk check-in will not be allowed in patient care areas
and will be asked to return home.
 Patients may be asked to reschedule nonurgent care if they or their visitor are
symptomatic.
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4 AJOG MFM MAY 2020a discussion of the altered risk/benefit
balance of coming to the office for testing
in the setting of a global pandemic.Section 4: Visitor policy for obstetric
outpatient office
Box 3 outlines the general guidelines for
visitors. In the setting of a pandemic,
consider visitors as something that does
not benefit patient care but may harm
other patients/providers. Exceptions
Clinical Perspectivemay be made when the visitor is critical
for patient care, for example, for young
patients coming with a parent or some-
one with developmental delay who relies
on a support person to aid in medical
decision making.
Section 5: Involvement of trainees
In setting of a COVID-19 and the sig-
nificant risk of not only trainees’ health
but also additional health care providersserving as a vector and using limited
protective equipment, we suggest all
nonessential clinical personnel remain at
home. This means any nursing, medical,
or sonography students should not be in
the office; any other observerships
should be suspended. Additionally, in an
academic setting in which an attending
physician is supervising residents or fel-
lows, multiple providers providing face-
to-face counseling should be limited. -ACKNOWLEDGMENT
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